Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-O rollover study of olaparib in oncology
CTR20254928Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in breast cancer, sponsored by AstraZeneca. Started Dec 2025; status: active.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254928.